Enovis (NYSE:ENOV – Get Rating) is one of 48 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it contrast to its rivals? We will compare Enovis to similar companies based on the strength of its earnings, analyst recommendations, dividends, valuation, institutional ownership, risk and profitability.
Insider and Institutional Ownership
50.9% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 8.2% of Enovis shares are held by company insiders. Comparatively, 10.9% of shares of all “Surgical appliances & supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Enovis and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for Enovis and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Enovis presently has a consensus price target of $67.00, suggesting a potential upside of 21.25%. As a group, “Surgical appliances & supplies” companies have a potential upside of 80.41%. Given Enovis’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Enovis has less favorable growth aspects than its rivals.
Volatility and Risk
Enovis has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Enovis’ rivals have a beta of 0.81, suggesting that their average stock price is 19% less volatile than the S&P 500.
Earnings & Valuation
This table compares Enovis and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Enovis||$3.85 billion||$71.66 million||41.86|
|Enovis Competitors||$1.29 billion||$145.66 million||32.67|
Enovis has higher revenue, but lower earnings than its rivals. Enovis is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Enovis rivals beat Enovis on 7 of the 13 factors compared.
About Enovis (Get Rating)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.